Clinical trials: Reactions Adverse
Carcinoid Syndrome
Study of Panitumumab in the Treatment of Carcinoid Syndrome
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide…
- Trial name
- NCT01172717
- Testing
- Panitumumab
- Where
- 2 sites in United States
- Sponsor
- Boston Medical Center
Diffuse Large B-Cell Lymphoma
Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma
This prospective, non-randomized diagnostic interventional study evaluates cognitive impairment in patients with diffuse large B-cell lymphoma (DLBCL) treated at the Institute of Oncology Ljubljana.
- Trial name
- NCT07443514
- Testing
- Structured Neurocognitive Assessment Battery, Psychometric Questionnaires, CSF Biomarker Analysis
- Where
- Slovenia
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute of Oncology Ljubljana
Advanced Neuroendocrine Neoplasm, Carcinoid Syndrome
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
This phase II trial studies the effect of retifanlimab and telotristat ethyl in treating patients with neuroendocrine tumors that have spread to other places in the body (advanced) and carcinoid syndrome.
- Trial name
- NCT04776876
- Testing
- Retifanlimab, Telotristat Ethyl
- Sponsor
- M.D. Anderson Cancer Center
Adverse Effect of Cardiovascular Medications (Diagnosis)
Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
In patients with coronary heart disease who were treated with PCSK9 inhibitor evolocumab for intensive lipid-lowering therapy, the changes of retinal microvessels were measured with OCTA (Optical Coherence Tomography…
- Trial name
- NCT05802108
- Testing
- Evolocumab combined with statins, Statin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zibo Central Hospital
Cis-Platinum Nephropathy, Mannitol Adverse Reaction
The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial
This study include cancer patients who had received chemotherapy that include cisplatin. Patients were randomly assigned to either a mannitol 20 g intravenous single dose after cisplatin or a placebo (saline).
- Trial name
- MACIN (NCT04251689)
- Testing
- Mannitol
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Cancer, Heart Failure
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To…
- Conditions
- Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy
- Trial name
- NCT06092606
- Testing
- Trial group: DH001 low-dose group, Trial group: DH001 high-dose group
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Monyan Pharmaceutical (Shanghai) Co., Ltd.
Dyslipidemias, Statin Adverse Reaction
Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
Statin intolerance occurs in up to 15-20% of treated patients. The combined use of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors with ezetimibe is commonly performed in these patients, and has been associated…
- Conditions
- Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases, Lipid Metabolism Disorders
- Trial name
- BESAFE (NCT06381947)
- Testing
- Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe, Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
- Volunteers
- 130 people
- Sponsor
- University of Salerno
Cocaine Use, Cocaine Intoxication
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department…
- Conditions
- Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse
- Trial name
- CATALYST (NCT06045793)
- Testing
- TNX-1300 (Injection)
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Anesthesia; Adverse Effect, Reflex, Abnormal
The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea
The aim of this study is to find the Effects of Anesthetics Used in Hypotensive Anesthesia on Stapes Reflex and Distortion Product Auto Acoustic Emission.
- Conditions
- Anesthesia; Adverse Effect, Reflex, Abnormal, Tinnitus, Spontaneous Oto-Acoustic Emission
- Trial name
- NCT02062333
- Testing
- Dexmedetomidine, esmolol
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- TC Erciyes University
Cardiac Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
The goal of this clinical research study is to learn if certain biomarker testing on blood samples can help to detect heart damage that may occur during chemotherapy.
- Trial name
- NCT01032278
- Testing
- Laboratory Biomarker Analysis, Questionnaires
- Where
- 2 sites in United States
- Volunteers
- 597 people
- Sponsor
- M.D. Anderson Cancer Center
Mycoses
Therapeutic Drug Monitoring of Voriconazole
The purpose of this study is to determine whether therapeutic drug monitoring of voriconazole is useful in the treatment of invasive fungal infection.
- Trial name
- NCT00890708
- Testing
- Voriconazole (therapeutic drug monitoring)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Seoul National University Hospital
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00052884
- Testing
- filgrastim, amifostine trihydrate, melphalan
- Where
- 16 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eastern Cooperative Oncology Group
HIV Infections
VENICE Study Nevirapine Full Dose/Dose Escalation
This study aims to compare the trough plasma concentrations of nevirapine after 7 days of treatment at the full dose from baseline with dose escalation in patients taking efavirenz who switch to nevirapine due to neuropsychiatric…
- Trial name
- VENICE (NCT00704249)
- Testing
- nevirapine
- Where
- 15 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Clinical Trial Agency of HIV Study Group
Anesthesia, Anesthesia; Adverse Effect
Dexamethasone vs Bicarbonate to Intracuff Lignocaine 2% in General Anaesthesia
This study is designed to evaluate and compare the effect on hemodynamics, extubation response and patients satisfaction score in patients with ETT cuff filled with either mixture of lignocaine with sodium bicarbonate or with a…
- Conditions
- Anesthesia, Anesthesia; Adverse Effect, Anesthesia Intubation Complication
- Trial name
- NCT03833947
- Testing
- lignocaine+bicarbonate, lignocaine+dexamethasone
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Aligarh Muslim University
Liver Transplant; Complications, Renal Insufficiency
Extended-Release Tacrolimus Following Liver Transplantation
Medications used after transplant to prevent rejection are associated with many side effects. Tacrolimus side effects include kidney dysfunction; tremor, headaches, difficulty sleeping, change in sensation (legs), seizure, or…
- Conditions
- Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction, Metabolic Syndrome
- Trial name
- NCT05242315
- Testing
- Envarsus Oral Product, Prograf (SOC)
- Where
- Canada
- Volunteers
- 94 people
- Sponsor
- University of Alberta
Adverse Drug Reaction
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested.
- Trial name
- INGenious (NCT02297126)
- Testing
- Pharmacogenetic Intervention Arm (pharmacogenetic testing)
- Where
- United States
- Volunteers
- 4,465 people
- Sponsor
- Indiana University
Drug-Related Side Effects and Adverse Reactions
Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma
This study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT03177174
- Testing
- Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Luo yanrong
Drug Hypersensitivity
Drug Provocation Test (DPT) to Paracetamol
Background : Paracetamol (acetaminophen) drug hypersensitivity reactions (DHR) are oonfirmed in about 10% of alleged cases. The diagnosis is made via an empirical drug provocation test (DPT).
- Trial name
- Paracetamol (NCT03771118)
- Where
- France
- Volunteers
- 498 people
- Sponsor
- University Hospital, Montpellier
Acute Drug-induced Liver Injury, Chronic Liver Disease
A Diagnostic Study on Patients With Drug-induced Liver Injury
This study is a multi-center, prospective, non-interventional cohort study with an estimated enrollment of 600 patients with acute DILI.
- Trial name
- NCT04526548
- Volunteers
- 600 people
- Sponsor
- Drug Induced Liver Disease Study Group
Immune System Diseases, COVID-19 Vaccine Adverse Reaction
COVID-19 Post-Vaccination Observation
The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis.
- Conditions
- Immune System Diseases, COVID-19 Vaccine Adverse Reaction, Immune System Disorder
- Trial name
- NCT06107348
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Yang I. Pachankis, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.